Picture of Nykode Therapeutics ASA logo

NYKD — Nykode Therapeutics ASA News Story

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Brief: Nykode Presents Additional Immunogenicity Data From VB-C-03 Trial

April 20 (Reuters) - Nykode Therapeutics ASA NYKD.OL:

PRESENTS VB-C-03 TRIAL DATA SHOWING 100% IMMUNOGENICITY IN 6 AND 9 MG DOSE GROUPS

ALL PATIENTS IN 6 AND 9 MG DOSE GROUPS SHOW HPV16-SPECIFIC IMMUNE RESPONSES

IMMUNE RESPONSES RAPID AND DURABLE, PERSISTING TO END-OF-TREATMENT

VB-C-03 TRIAL DEMONSTRATED CONFIRMED OBJECTIVE RESPONSE RATE OF 38.5%

Source text: ID:nObir2hCha

Further company coverage: NYKD.OL

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Nykode Therapeutics ASA

See all news